NCI CTEP-Approved Trials for the Month of May
Introducing palliative care shortly after a cancer diagnosis results in better quality of life and fewer depression symptoms for family caregivers, according to a randomized clinical trial.
A meta-analysis of 346 phase I clinical trials, involving more than 13,000 patients, found that selecting treatment based on a tumor's molecular characteristics led to significantly better outcomes.
An independent data monitoring committee found that a phase III trial of LEE011 (ribociclib) had met its primary endpoint of improving progression-free survival in patients with advanced breast cancer, and recommended that it be stopped early.
WT1 Vaccine Doubles PFS in Phase II Trial
Long-term follow-up from a phase Ib trial in newly diagnosed and previously treated patients with advanced melanoma showed that 40 percent of patients were alive three years after starting Keytruda (pembrolizumab), with similar 36-month overall survival rates in both groups.
Results from a pre-specified interim analysis from the phase III J-ALEX study found that Alecensa (alectinib) reduced the risk of disease worsening or death by 66 percent compared to (Xalkori) crizotinib in Japanese people with advanced or recurrent ALK-positive non-small cell lung cancer (HR=0.34, 99% CI: 0.17-0.70, p<0.0001) who had not received prior treatment with an ALK inhibitor.
FDA granted accelerated approval to Tecentriq (atezolizumab) for urothelial carcinoma, the most common type of bladder cancer. This is the first product in its class of PD-1/PD-L1 inhibitors approved to treat this type of cancer, according to the drug's sponsor, Genentech.
A retrospective analysis found that the location of the primary tumor within the colon predicts survival and may help inform optimal treatment selection for patients with metastatic colorectal cancer.
Early findings from a phase III clinical trial showed that patients with multiple myeloma who received an autologous stem cell transplant survived longer without disease progression than those who received only chemotherapy using novel agents.
